Jagsonpal Pharmaceuticals Ltd.

₹ 250.00

Buy Back of Shares Inter alia considered and approved the proposal for buyback of equity shares of the Company in compliance with Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 (SEBI Buyback Regulations), subject to approval of the shareholders and other applicable statutory approvals, as may be required. The details pertaining to proposed Buyback is as under 1. Upto 16,00,000 (16 lakhs) equity shares (representing 2.39% of the paid-up equity capital of the Company 2. Buy back Price : Rs. 250.00 per equity shares (Rupees Two Hundred and Fifty Only) 3. Maximum Buyback Offer size : Rs. 40,00,00,000 (Rupees Forty Crores only), representing 18.35% of the paid-up equity share capital and free reserves as per audited financial statements as at March 31, 2025 The Maximum Buyback Offer Size does not include expenses such as brokerage costs, fees, turnover charges, securities transaction tax, goods and services tax (if any), stamp duty, filing fees payable to SEBI, stock exchange charges, advisors? and legal fees, printing and dispatch expenses, public announcement publication expenses and other incidental and related expenses. Method of Buyback The Buyback will be undertaken through the ?tender offer? route on a proportionate basis in accordance with the provisions of the SEBI Buyback Regulations Other details: ? Centrum Capital Limited, a SEBI registered Merchant Banker, has been appointed as the Manager to the Buyback. ? The Board has constituted a ?Buyback Committee? and delegated necessary powers to it, including fixing the record date and undertaking actions in relation to the proposed Buyback. ? Mr. Pratham Rawal, Company Secretary & Compliance Officer, has been designated as the Compliance Officer for the Buyback. ? The Promoters/Promoter Group will not be participating in the proposed Buyback. ? Details of Postal ballot for seeking shareholder approval for the proposed Buyback will be intimated separately